In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 1.07 million shares were traded.
Ratios:
To gain a deeper understanding of ACRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 3.99. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On December 23, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Leonard Braden Michael bought 206,025 shares of ACRS for $256,357 on Aug 05 ’24. The 10% Owner now owns 14,250,000 shares after completing the transaction at $1.24 per share. On Aug 02 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 167,544 shares for $1.29 each. As a result, the insider paid 216,400 and bolstered with 14,043,975 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.40 while its Price-to-Book (P/B) ratio in mrq is 0.89.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is -14.76%, while the 200-Day Moving Average is calculated to be -32.87%.
Shares Statistics:
A total of 107.85M shares are outstanding, with a floating share count of 91.67M. Insiders hold about 15.34% of the company’s shares, while institutions hold 69.04% stake in the company.
Earnings Estimates
The dynamic stock of Aclaris Therapeutics Inc (ACRS) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.58 and -$0.64 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.76, with 3.0 analysts recommending between -$0.67 and -$0.87.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $3.55M. It ranges from a high estimate of $9.7M to a low estimate of $600k. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $2.4MFor the next quarter, 4 analysts are estimating revenue of $3.62M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $600k.
A total of 5 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $40.7M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $14.38M. In the same quarter a year ago, actual revenue was $18.72MBased on 4 analysts’ estimates, the company’s revenue will be $14.4M in the next fiscal year. The high estimate is $44.7M and the low estimate is $900k.
